Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus chemotherapy/TKI/immunotherapy in advanced non-squamous NSCLC (real-world, retrospective)
ChiCTR2400085138Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Progression-free survival and Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085138.